| Renal and ureteric stones | QS195 | | |
| Artificial iris insertion for acquired aniridia | IPG674 | | |
| Artificial iris insertion for congenital aniridia | IPG675 | | |
| Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis | ES29 | | |
| Specialist neonatal respiratory care for babies born preterm | QS193 | | |
| CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic | MIB219 | | |
| Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
| Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
| Ranibizumab for treating diabetic retinopathy (terminated appraisal) | TA637 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA634 | | |
| Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
| Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | TA636 | | |
| Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia | MTG49 | | |
| Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA626 | | |
| MolecuLight i:X for wound imaging | MIB212 | | |
| Actim Pancreatitis for diagnosing acute pancreatitis | MIB218 | | |
| Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) | DG39 | | |
| Ustekinumab for treating moderately to severely active ulcerative colitis | TA633 | | |
| Generalised anxiety disorder and panic disorder in adults: management | CG113 | | |
| Archimedes for biopsy of suspected lung cancer | MIB211 | | |
| Intravenous fluid therapy in children and young people in hospital | NG29 | | |
| Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
| Joint replacement (primary): hip, knee and shoulder | NG157 | | |